ghk-cu tolerance desensitization downregulation long-term use Expression and Purification of Recombinant GHK Tripeptides Are ghk-cu peptide tolerance desensitization receptor

This is highly speculative because: Oral bioavailability differs between species Route of administration affects systemic exposure Species differences in peptide metabolism and clearance are unknown Current Practice Patterns Current practice patterns from unregulated sources typically involve: Subcutaneous injection: 0.25-0.5 mg once or twice daily, administered near injection sites for localized effects or abdominally for systemic distribution

A U-100 insulin syringe with half-unit or fine gradations makes this dose far easier to measure accurately than a standard 1 mL syringe

Various structural alterations were made at the N-terminal such as substitution of D-norleucine for L-norleucine, N-acetylation of norleucine, and replacement of norleucine with GABA in order to improve overall stability by reducing susceptibility to aminopeptidases

Most failures dont come from bad intent